

Esther H Lips

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8850869/publications.pdf>

Version: 2024-02-01

28
papers

1,106
citations

567281

15
h-index

526287

27
g-index

28
all docs

28
docs citations

28
times ranked

2171
citing authors

#	ARTICLE	IF	CITATIONS
1	Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance. <i>Npj Breast Cancer</i> , 2022, 8, 60.	5.2	11
2	Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests. <i>Oncogene</i> , 2022, 41, 3498-3506.	5.9	9
3	Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer. <i>Nature Genetics</i> , 2022, 54, 850-860.	21.4	34
4	Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab010.	2.9	21
5	Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ. <i>Npj Breast Cancer</i> , 2021, 7, 31.	5.2	11
6	Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breast. <i>British Journal of Cancer</i> , 2021, 125, 1443-1449.	6.4	6
7	Ovarian Cancer-Specific BRCA-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 6559-6569.	7.0	9
8	Prognostic value of histopathological DCIS features in a large-scale international interrater reliability study. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 759-770.	2.5	16
9	BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 79.	5.0	8
10	Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 60.	5.2	9
11	Radiogenomic Analysis of Breast Cancer by Linking MRI Phenotypes with Tumor Gene Expression. <i>Radiology</i> , 2020, 296, 277-287.	7.3	37
12	The impact of patient characteristics and lifestyle factors on the risk of an ipsilateral event after a primary DCIS: A systematic review. <i>Breast</i> , 2020, 50, 95-103.	2.2	7
13	Reliability of preoperative breast biopsies showing ductal carcinoma in situ and implications for non-operative treatment: a cohort study. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 409-418.	2.5	16
14	Ductal carcinoma in situ: to treat or not to treat, that is the question. <i>British Journal of Cancer</i> , 2019, 121, 285-292.	6.4	168
15	Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma in Situ: A Nested Case-Control Study. <i>Clinical Cancer Research</i> , 2018, 24, 3593-3601.	7.0	30
16	Enrichment of high-grade tumors in breast cancer gene expression studies. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 327-335.	2.5	5
17	Functional Ex Vivo Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene Defects. <i>Clinical Cancer Research</i> , 2018, 24, 6277-6287.	7.0	53
18	Mammary tumor-derived CCL2 enhances pro-metastatic systemic inflammation through upregulation of IL1 β in tumor-associated macrophages. <i>Oncolmmunology</i> , 2017, 6, e1334744.	4.6	81

#	ARTICLE	IF	CITATIONS
19	Evaluation of the EGFR polymorphism R497K in two cohorts of neoadjuvantly treated breast cancer patients. PLoS ONE, 2017, 12, e0189750.	2.5	8
20	Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer. Journal of the National Cancer Institute, 2016, 108, djw148.	6.3	157
21	Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response. Breast Cancer Research, 2015, 17, 134.	5.0	58
22	Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms. Molecular Oncology, 2015, 9, 1274-1286.	4.6	29
23	Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy. Breast Cancer Research, 2014, 16, R47.	5.0	86
24	Platform comparisons for identification of breast cancers with a BRCA-like copy number profile. Breast Cancer Research and Treatment, 2013, 139, 317-327.	2.5	20
25	SERPINA6, BEX1, AGTR1, SLC26A3, and LAPT4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer. Breast Cancer Research and Treatment, 2013, 137, 213-223.	2.5	52
26	Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer. Breast Cancer Research and Treatment, 2012, 136, 35-43.	2.5	88
27	Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness. Breast Cancer Research, 2011, 13, R107.	5.0	72
28	Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk. British Journal of Cancer, 0, , .	6.4	5